secwatch.observer — SEC 8-K summary
======================================

Issuer:     Q32 Bio Inc. (QTTB)
CIK:        0001661998
Form:       8-K
Filed at:   2025-03-11T23:59:59+00:00
Accession:  0000950170-25-036819
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Q32 Bio Q4 2024 net loss $14.2M; cash $78M funds into 2H2026; bempikibart AA data encouraging
--------------------------------------------------------------------------------

- Cash and cash equivalents $78.0M as of Dec 31, 2024, expected to fund operations into 2H'26.
- Net loss $14.2M ($1.16 per share) for Q4 2024 vs $27.1M ($76.39) in Q4 2023.
- SIGNAL-AA Part B dosing on track for 1H'25; topline data expected 1H'26.
- Phase 2a Part A data presented at AAD showed durable responses post-treatment (median follow-up 41 weeks).
- Bempikibart well-tolerated; no grade 3+ related AEs or related viral infections.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1661998/000095017025036819/0000950170-25-036819-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1661998/000095017025036819/qttb-20250311.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-036819

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer